Publisher Future Science Group has announced that it will continue to require double-blind peer review for research articles submitted to all 34 professional journals published by both of its imprints, Future Science and Future Medicine. FSG has employed the use of double-blind peer review since the launch of the company's first journal, Pharmacogenomics, in 2000.
Recently, a few major scientific journals have announced plans to use double-blind review, in which both the authors and the reviewers are made anonymous. Future Science Group journals have always followed the double-blind system in order to remove bias, intentional or unintentional, from the process.
Single blind peer review is still used by many scientific journals. In single-blind peer review, manuscripts are sent to reviewers for assessment with the authors' information included, but the peer reviewers themselves are anonymous.
As well as conducting double-blind review, Future Science Group also aims to obtain a minimum of three reviewers for each submission, to ensure each paper is thoroughly assessed before a publication decision is made.
